upgrad overweight risk remain reward full attent
upgrad overweight chang target still fan
combin risk inherit busi think bottom
sort found name stock around dividend yield
firm manag commit increas trade ep
go forward rather vocal variou pressur point
humira busi think great opportun pivot narr toward
success launch skyrizi rinvoq upadacitinib combin
rather durabl botox cosmet franchis go forward like opportun
share rebound buyer level approach
first choic havent shi express
skeptic strateg rational behind abbv acquisit see prior
note inde still arent exactli enthusiast combin given agn
uniqu challeng includ product inherit said
aspect deal includ immedi ep accret year
peak cost reduct caught attent share trade current
level think risk/reward skew upsid
valuat attent gener hate valuat call one cant
ignor share trade ntm consensu ep all-tim
low signific discount large-cap biotech current
ep pharma ep abbv dividend yield particularli
glare mark clear departur abbv histor averag level
seen among pharma sinc see situat dont believ last
note even target abbv dividend yield would remain attract
humira concern seem well known one two big launch
drive upsid secret humira busi face pressur ex-u
biosimilar us increas use new moa rheum derm gi
indic said expect big thing skyrizi newly-approv rinvoq
spherix survey work indic robust uptak store psoriasi ra respect
inde skyrizi remark launch first subsequ
increas guidanc seem valid feedback give
opportun chang narr away flag humira perform
bottom line think stock bottom chang model
target deriv appli rel modest multipl ep
buyer stock think share overreact downsid
follow acquisit announc work
commerci regulatori clinic ip risk associ market pipelin product
fulli integr biopharmaceut compani
ep discount back
year
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
attent
share trade ntm consensu ep signific discount large-
cap biotech pharma see exhibit note essenti repres
all-tim low well histor rang even gild valuat
basi abbv valuat also appear attract well see exhibit
among large-cap biotech name celg trade lower large-cap biotech
averag trade pharma name gener around even exclud
outlier averag large-cap biotech matter way
data slice trade steep discount peer
view abbv dividend yield particularli glare though expect detail
financi guidanc deal wont avail close next year manag made
clear maintain grow dividend top prioriti show exhibit us
pharma name histor trade dividend yield thu
current dividend yield mark sharp departur norm us pharma dividend yield
rare exceed inde last time saw financi crisi
think get investor attent point perspect even share trade
target abbv dividend yield would remain attract
put togeth gener fan valuat call case abbv
valuat becom compel us ignor prompt upgrad overweight
large-cap pharma valuat
page
scienc pharmajnjjohnson co lilli squibb pharmarog-swxroch hold ag sponsor plc sponsor plc sponsor exclud average/median calcul outlier roch sanofi bayer price market cap ep repres local currencynot ep growth calcul compound-annual-growth-rate factset estim epsep growth cap ytd perform exhibit
page
good sold
product sale
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
dollar except per share data
row revenu
elotuzumab revenu
total ww elotuzumab revenu
row profit shaqe
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
